Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021.
For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss the Poseidon Trial, a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.